Lung Cancer

The deep learning survival neural network model demonstrated the potential to provide personalized treatment recommendations based on real clinical data in patients with non-small cell lung cancer.

Patients with chemotherapy-naïve, locally advanced, or metastatic non-small cell lung cancer who were treated with tiragolumab plus an anti-PD-L1 agent showed better efficacy versus single-agent checkpoint inhibitor therapy alone.

The findings support ctDNA testing in patients who are undergenotyped at the time of diagnosis and as a primary option at the time of progression on targeted therapies.

Fam-trastuzumab deruxtecan-nxki (Enhertu) showed favorable clinical activity with a high objective response rate and durable responses in patients with HER2-mutated non-small cell lung cancer.

The study demonstrated modest survival benefits in patients with extensive-stage small cell lung cancer who received the combination of pembrolizumab and etoposide plus platinum (EP).

The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.

Combining tislelizumab with chemotherapy improved progression-free survival compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non-small cell lung cancer.

Patients enrolled in this open-label trial have p53-mutated extensive disease small cell lung cancer (SCLC) and are being treated with second-line topotecan following administration of ALRN-6924.

Tepotinib demonstrated durable clinical activity in patients with locally advanced or metastatic non-small cell lung cancer who harbor a MET exon 14 skipping mutation identified through liquid or tissue biopsy.

The updated findings indicated that alectinib demonstrated a clinically meaningful improvement in overall survival compared with crizotinib in patients with ALK-positive non-small cell lung cancer.

In this examination of 102 patients with lung cancer and COVID-19, researchers found that COVID-19 is associated with high burden of severity in this patient population.

This study found that cancer screening decisions among older adults with limited life expectancy were not always informed or intentional and were subject to multiple complex factors.

The FDA approved lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer under accelerated approval based on overall response rate and duration of response in a phase 2 study.

Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed the future of lung cancer treatment to follow the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.

In this retrospective cohort study, the use of immune checkpoint inhibitors among patients with advanced NSCLC with negative, low, or untested PD-L1 expression was found to have increased over time.

The FDA approved ramucirumab injection in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 mutations.

Payment models with shared-savings components, such as the Oncology Care Model, may be associated with fewer visits and lower costs in certain cancer settings in the first year.

The FDA approved the use of nivolumab plus ipilimumab given with 2 cycles of platinum-doublet chemotherapy as a first-line treatment for adult patients with metastatic or recurrent non-small cell lung cancer.

This study suggested that Medicaid expansion could have survival benefits for men with non-small cell lung cancer, however the same association pattern was not observed for women.

The FDA has approved brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer, as detected by an FDA-approved test.

A phase II study indicated that low-dose erlotinib (Tarceva) appears to be safe and effective in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer.

Given these findings, researchers indicated that continuous education around molecular testing in lung cancer should be intensified on both national and international levels to ensure patients receive optimal therapy.

A recent examination of older adults with cancer found accelerated losses in differing sarcopenia measures existed before and after a cancer diagnosis.

Atezolizumab was approved as a first-line treatment for adults with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, as determined by an FDA approved test, with no EGFR or ALK genomic tumor aberrations.

The FDA approved the combination of nivolumab plus ipilimumab as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (≥1%), as determined by an FDA-approved test.

ONCOLOGY® recently sat down with David R. Gandara, MD, director of the thoracic oncology program and senior advisor to the director of the University of California (UC) Davis Comprehensive Cancer Center, to discuss the impact of the pandemic on the current management and treatment of patients with lung cancer, as well as the future of education and patient care in a post–COVID-19 world.

The FDA approved the first therapy to treat cancers with rearranged during transfection (RET) gene alterations.

In this study, the feasibility and safety of DETECT-A coupled with PET-CT imaging to detect cancer was evaluated using a prospective, interventional study of 10,006 women not previously known to have cancer.

The FDA granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer.

This study suggested that identifying which lung cancer screening options are generally more attractive to patients may increase screening.